Syngulon and ULB announce the issuance by the USPTO on March 19, 2024 of US Patent 11,932,672 covering an antibiotic-free selection technology based on bacteriocin/immunity for the production of recombinant protein or pDNA. SERAING, Belgium and CHARLEROI, Belgium, May 20, 2024…
Syngulon and ULB announce the issuance by the USPTO of a first joint patent covering an antibiotic-free selection technology
This post was originally published on this site